Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polo-like kinase 1 is a potential therapeutic target in human melanoma.

The Journal of investigative dermatology - 1 Sept 2011

Jalili Ahmad, Moser Anna, Pashenkov Mikhail, Wagner Christine, Pathria Gaurav, Borgdorff Viola, Gschaider Melanie, Stingl Georg, Ramaswamy Sridhar, Wagner Stephan N

Abstract excerpt

Exploration of the human melanoma cell-cycle pathway can lead to identification of new therapeutic targets. By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1) to be significantly overexpressed in primary melanomas and in melanoma metastases. In vitro expression of Plk-1 was peaked at the G2/M phase of the cell cycle. Plk-1 knockdown/inhibition led to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to Flavonoids

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to G1 Phase

Share to Gene Expression Regulation, Enzymologic

Share to MAP Kinase Signaling System

Share to Nevus, Pigmented

Share to Polo-Like Kinase 1

Share to RNA, Small Interfering

Source

Identifiers

PMID: 21654832
DOI: 10.1038/jid.2011.136

Genes

BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polo-like kinase 1 is a potential therapeutic target in human melanoma.PMID 21654832Read ↗

Polo-like kinase 1 (Plk1) in non-melanoma skin cancersSemantic proximity Read ↗

PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma PathwaysSemantic proximity Read ↗

Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma CellsSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.Semantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read ↗

Targeting Polo-like Kinase in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.